Quantcast

Latest Genomic Health Inc. Stories

2014-09-12 08:23:43

Results Suggest that Oncotype DX® Colon Cancer Test May Reduce Medical Costs Associated with Stage II Disease While Increasing Patient Well-being REDWOOD CITY, Calif., Sept. 12, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that PharmacoEconomics published positive results from a health economic analysis suggesting that use of the Oncotype® DX colon cancer test may result in a significant reduction in direct medical costs and improve patient quality of...

2014-09-09 08:31:36

Additional Data Acceptances Include Multiple Oncotype DX® Studies in Breast and Renal Cancers REDWOOD CITY, Calif., Sept. 9, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that results from nine studies of Oncotype DX(®) in prostate, breast and renal cancers will be presented at the European Society for Medical Oncology (ESMO) 2014 Congress in Madrid, September 26 - 30. Included in the program is the first presentation of strongly positive results from an...

2014-08-19 12:28:27

First Kit Improves RNA-Seq for FFPE and High-Quality RNA Samples IPSWICH, Mass., Aug. 19, 2014 /PRNewswire/ -- New England Biolabs, Inc. (NEB(®)) today announced that NEB has exclusively in-licensed rights from Genomic Health, Inc. to its technology for the depletion of abundant RNAs, which is instrumental to performing sensitive RNA-seq experiments at a lower cost. http://photos.prnewswire.com/prnvar/20090921/NE79207LOGO-b Ribosomal RNAs (rRNAs) are extremely abundant,...

2014-08-08 08:26:06

REDWOOD CITY, Calif., Aug. 8, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that Brad Cole, Chief Operating Officer and Chief Financial Officer, will present at the 34(th) Annual Canaccord Growth Conference in Boston on Wednesday, August 13 at 10:30 a.m. Eastern Time (ET). http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO To access the live and subsequently archived webcast of the conference call, go to the Investor Relations section of the...

2014-08-07 16:28:34

17% Increase in Test Volume, 11% Increase in Total Revenue and 29% Increase in International Product Revenue Compared to Prior Year REDWOOD CITY, Calif., Aug. 7, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today reported financial results and business progress for the quarter ended June 30, 2014. Product revenue was $70.5 million in the second quarter of 2014, compared with $63.7 million for the second quarter of 2013, an increase of 11 percent. There was no contract revenue in...

2014-08-06 08:31:58

Study Achieved Primary Endpoint of Predicting Recurrence after Surgery and Reconfirmed Original Adverse Pathology Endpoint from Published UCSF Validation Study REDWOOD CITY, Calif., Aug. 6, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from an additional independent clinical validation study conducted by the Center for Prostate Disease Research (CPDR) demonstrating that the Oncotype DX(®) Genomic Prostate Score (GPS) predicts...

2014-07-31 08:35:54

REDWOOD CITY, Calif., July 31, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced that the company will host a conference call and webcast on Thursday, August 7 at 4:30 p.m. Eastern Time to discuss its second quarter 2014 financial results. The call and webcast will follow the release of the second quarter financial results after market close. http://photos.prnewswire.com/prnvar/20130425/SF01493LOGO Conference Call DetailsTo access the live conference call on...

2014-06-11 08:29:34

Complete Data to be Submitted for Presentation at the 2014 San Antonio Breast Cancer Symposium REDWOOD CITY, Calif., June 11, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced positive preliminary results from a second large, independent clinical validation study of Oncotype DX® in patients with a pre-invasive form of breast cancer, also known as DCIS (ductal carcinoma in situ). The study, conducted by the Ontario DCIS Study Group in Canada, met its primary...

2014-06-03 08:32:24

Two Studies Presented at ASCO® Demonstrate Company's Ability to Develop Tests to Predict Disease Aggressiveness Across Various Cancers REDWOOD CITY, Calif., June 3, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of two studies demonstrating the ability of its Oncotype DX(®) test and a new 16-gene panel to predict disease aggressiveness and clinical outcomes in prostate and renal cancers, respectively. These results, presented at the American...

2014-06-01 08:20:43

New Study Shows Oncotype DX® DCIS Score(TM) Changes Treatment Recommendations for One Out of Three DCIS Patients REDWOOD CITY, Calif., June 1, 2014 /PRNewswire/ -- Genomic Health, Inc. (Nasdaq: GHDX) today announced results of six studies being presented at the 2014 American Society of Clinical Oncology(®) (ASCO(®)) Annual Meeting taking place May 30 - June 3 in Chicago, underscoring the practice-changing value of Oncotype DX(®)( )in pre-invasive and invasive breast cancer and colon...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related